



EATRIS Infrastructure bridges Basic Research and Medical Innovation



EATRIS

European
Advanced Translational
Research Infrastructure in Medicine





Infrastructure in Translational Medicine

The goal of EATRIS, **European Advanced Translational Research InfraStructure in Medicine**, is to provide a highly productive research infrastructure to enable a faster and more efficient translation of basic biomedical research discoveries into new innovative medicinal products. To achieve this EATRIS engages leading translational research centres and hospitals to provide key preclinical and clinical facilities as well as translational expertise necessary to support the development of new preventive, diagnostic or therapeutic strategies. Unmet medical needs in the most important disease areas and fields of research as well as in rare diseases will drive EATRIS' development policy.

Unique Approach of Opening the Doors


EATRIS will operate through a framework of Translational Centres across Europe which will be open to researchers worldwide to develop their discoveries into products. This comprises not only broad access to state-of-the-art facilities and technologies but also training and supporting services to optimise the output of both basic and clinical research. Thus EATRIS will enable academic institutions to create material value and real clinical benefit out of their research. In addition, EATRIS will give industry the opportunity to use the sophisticated and specialised facilities of the EATRIS research environment and will encourage more cooperation with academia.

The EATRIS Translation Centres

The EATRIS Translation Centres will specialise in products such as diagnostics, small molecule drugs, biologics, vaccines or advanced therapy medicinal products like cell therapies and ensure that their core expertise covers the entire respective development chain.

The unique package of infrastructure and services for scientists will consist of

- State-of-the-art facilities covering the entire development chain from validation facilities, tracer centres, compound libraries, GMP etc. to research hospitals,
- Expert knowledge in fields such as regulatory issues and product development and
- Training programmes for scientists as well as technicians and nurses.



EATRIS Services


EATRIS supports projects from discovery (Proof of Principle) to clinical trial (Phase I/IIa). The projects will be selected on a competitive basis and will be reviewed

regularly regarding their potential of a successful development. From the beginning a project manager experienced in product development will guide the whole process together with a multidisciplinary team. Professional management for each translational project will ensure that quality is maintained and development proceeds in a timely way.

EATRIS acts as one


The supply of research support by EATRIS is harmonised, facilities for research are largely complementary. The central management "EATRIS Coordination & Support" serves as an entrance portal for external scientists and other customers ("one door"). Close interaction with industry will ensure a smooth and efficient commercial take-up of EATRIS products.

One Stop Shop Model



EATRIS Scientific Partners

- Atomic Agency Commission (CEA), France
- Centre for Translational Molecular Medicine (CTMM), Netherlands
- German Cancer Research Centre (DKFZ), Germany
- Helmholtz Centre for Infection Research (HZI), Germany
- Imperial College London, UK
- Institute for Molecular Medicine Finland (FIMM), Finland
- Istituto Superiore di Sanità (ISS), Italy
- Karolinska Institute (KI), Sweden
- University Hospital Vall d'Hebron (FIR-HUVH), Spain
- University of Copenhagen, Cluster for Molecular Imaging (CMI), Denmark
- University of Oslo (UiO), Norway



EATRIS Time Frame

Currently, EATRIS is in the Preparatory Phase. At the end of 2010 it will enter the Implementation Phase (2011-2015) during which the different EATRIS Translation Centres will initiate the first user projects to phase in the operation and gradually expand their capacities, leading to the establishment of full coverage of the necessary technological facilities. By 2016, EATRIS will be fully operational and offer support on a regular basis. It will be an innovation core for new diagnostics and therapies, being attractive for both researchers and industry.



Goals of EATRIS

EATRIS aims to facilitate that more innovative approaches from academic research find their way to healthcare applications. The medical need and the wellbeing of the population is the driving force for EATRIS developments. By linking basic and clinical researchers and creating a true cross-disciplinary environment, EATRIS will support and advance the translational research culture in Europe. EATRIS will take up promising discoveries across Europe and will increase significantly the number of high-potential translational projects. At the same time EATRIS “de-risks targets for industry” as drug candidates from academia will be more advanced on the translational path and developed following high quality standards.

EATRIS will strengthen the European biomedical research and health industry and will bring real clinical benefit to patients.



For further information please contact:

EATRIS Project Management
Helmholtz Centre for Infection Research (HZI)
Inhoffenstr. 7 ■ 38124 Braunschweig, Germany
mail: info@eatris.eu
phone: +49 (0)531 6181-1004
www.eatris.eu

